NGL FINECHEM
Back to Cashflow Statement
|
NGL FINECHEM Last 5 Year Cash Flow from Financing Activities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Cash Flow from Financing Activities | ₹30 Cr | ₹37 Cr | ₹-1.08 Cr | ₹-1.08 Cr | ₹-1.08 Cr |
What is the latest Cash Flow from Financing Activities ratio of NGL FINECHEM ?
| Year | Cash Flow from Financing Activities |
|---|---|
| Mar2026 | ₹30 Cr |
| Mar2025 | ₹37 Cr |
| Mar2024 | ₹-1.08 Cr |
| Mar2023 | ₹-1.08 Cr |
| Mar2022 | ₹-1.08 Cr |
How is Cash Flow from Financing Activities of NGL FINECHEM Trending?
| Years | Cash Flow from Financing Activities | % Change | |
|---|---|---|---|
| Mar2026 | ₹30 Cr | -21.15 | |
| Mar2025 | ₹37 Cr | Positive | |
| Mar2024 | ₹-1.08 Cr | Negative | |
| Mar2023 | ₹-1.08 Cr | Negative | |
| Mar2022 | ₹-1.08 Cr | - | |
Compare Cash Flow from Financing Activities of peers of NGL FINECHEM
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NGL FINECHEM | ₹2,126.1 Cr | 4.5% | 7.1% | 170.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹467,630.0 Cr | -0.1% | 0.5% | 14% | Stock Analytics | |
| DIVIS LABORATORIES | ₹218,972.0 Cr | -0.9% | 21.1% | 25.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹188,358.0 Cr | -1.3% | 1.1% | 32.7% | Stock Analytics | |
| CIPLA | ₹118,916.0 Cr | 0.2% | 2.1% | -5.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹97,824.0 Cr | 0.2% | -7.7% | -7.5% | Stock Analytics | |
NGL FINECHEM Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NGL FINECHEM | 4.5% |
7.1% |
170.4% |
| SENSEX | 0.5% |
2.6% |
-3.7% |
You may also like the below Video Courses